A Study of JNJ-75276617 in Participants With Acute Leukemia
Status:
Recruiting
Trial end date:
2024-12-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of
JNJ-75276617 in Part 1 (Dose Escalation) and to determine safety and tolerability at the
RP2D(s) in Part 2 (Dose Expansion).